Back to Search Start Over

New guaiane-type sesquiterpenoid dimers from Artemisia atrovirens and their antihepatoma activity

Authors :
Lihua Su
Xintian Zhang
Yunbao Ma
Changan Geng
Xiaoyan Huang
Jing Hu
Tianze Li
Shuang Tang
Cheng Shen
Zhen Gao
Xuemei Zhang
Ji-Jun Chen
Source :
Acta Pharmaceutica Sinica B, Vol 11, Iss 6, Pp 1648-1666 (2021)
Publication Year :
2021
Publisher :
Elsevier, 2021.

Abstract

Leading by cytotoxicity against HepG2 cells, bioactivity-guided fractionation of the EtOAc fraction from Artemisia atrovirens led to the isolation of 18 new guaianolide dimers, artematrolides A–R and lavandiolides A, B, C, H, and J. Eight compounds (1, 4, 10, 12, 13, and 19–21) were unambiguously confirmed by the single-crystal X-ray diffraction analyses, and the others were elucidated based on IR, UV, HRESIMS, 1D and 2D NMR experiments, and comparison of the experimental and calculated ECD data. Structurally, all of them were [4 + 2] Diels–Alder adducts of two monomeric guaianolides. The isolates were evaluated for their cytotoxicity against three human hepatoma cell lines, and 19 compounds demonstrated cytotoxicity against HepG2, SMMC-7721, and Huh7 cell lines. Especially, compounds 1, 12, 14, and 15 exhibited cytotoxicity with IC50 values of 4.4, 3.8, 7.6, and 6.7 μmol/L (HepG2), 9.6, 4.6, 6.6, and 6.0 μmol/L (SMMC-7721), and 7.6, 4.5, 6.9, and 5.6 μmol/L (Huh7), respectively. Notably, compound 12 showed the most promising activity against three human hepatoma cell lines and dose-dependently inhibited cell migration and invasion, induced G2/M cell cycle arrest and cell apoptosis in HepG2 cells, down-regulated the expression of BCL-2 and PARP-1, and activated PARP-1 to up-regulate the expression of cleaved-PARP-1.

Details

Language :
English
ISSN :
22113835
Volume :
11
Issue :
6
Database :
Directory of Open Access Journals
Journal :
Acta Pharmaceutica Sinica B
Publication Type :
Academic Journal
Accession number :
edsdoj.5d722d7e172547c29b7252cd6b51228a
Document Type :
article
Full Text :
https://doi.org/10.1016/j.apsb.2020.12.006